NASDAQ : GELS
Gelteq Limited — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · Australia
Last price 0.506 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.66M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
Details
| Name | Gelteq Limited |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 8 |
| Founded | 2018 |
| Ipo Date | 2024-10-29 |
| Ceo | Nathan Givoni |
| Country | Australia |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| Ipo Price | 4.00 |
| Isin | AU0000218109 |
| Cik | 1920092 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Nathan Jacob Givoni | Co-Founder, Chief Executive Officer and Executive Director |
| Simon Hayden Szewach | Co-Founder and Non-Executive Chairman |
| Thuy-Linh Gigler | Chief Financial Officer |
| Dr. Paul M. Wynne Ph.D. | Chief Scientific Officer |
| Bradley Glenn Karp | Head of Sales and Marketing |
| Adam Bendell | President of U.S. Operations |
| Matthew Jones | Head of Sports Performance |
Contact
| Address | Monash Innovation Labs, G.60, 22 Alliance Lane, Clayton, VIC 3800 , Australia |
| Phone | 61 3 9087 3990 |
| Website | https://www.gelteq.com |